<DOC>
	<DOCNO>NCT00019604</DOCNO>
	<brief_summary>RATIONALE : Radiofrequency ablation procedure heat tumor several degree body temperature may kill tumor cell . PURPOSE : Phase II trial study effectiveness radiofrequency ablation treat patient unresectable primary metastatic liver cancer .</brief_summary>
	<brief_title>Radiofrequency Ablation Treating Patients With Unresectable Primary Metastatic Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate nature duration response patient primary metastatic liver neoplasm , candidate surgical resection , treat radiofrequency interstitial tissue ablation . - Evaluate ability dynamic magnetic resonance imaging ( MRI ) ass effect therapy tumor blood flow tumor vascular density patient . - Determine ability positron emission tomography fludeoxyglucose F 18 ( FDG-PET ) monitor response treatment therapy patient . - Compare FDG-PET result compute tomography ( CT ) scan , biopsy , serum marker result patient treated therapy . - Compare performance FDG-PET CT scan MRI , term ability ass efficacy therapy patient . OUTLINE : Lesions target ultrasound radiofrequency ablation needle insert lesion heat target temperature great 60 degree C 15 minute , though exposure time may vary depend temperature achieve . To achieve 1 cm margin ablate tissue around lesion , multiple ablation course may perform , depend size lesion time required complete treatment . Patients undergo magnetic resonance image gadopentetate dimeglumine contrast , CT scan , ultrasound , positron emission tomography fludeoxyglucose F 18 baseline , 6 week , every 3 month 1 year , every 6 month 2 year . Patients follow 6 week , every 3 month 1 year , every 6 month 2 year evidence recurrence . PROJECTED ACCRUAL : A total 58 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary metastatic liver lesion Not candidate surgical resection Must six few lesion single lesion great 7 cm diameter Extrahepatic disease allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 50,000/mm^3 Prothrombin time ( PT ) partial thromboplastin time ( PTT ) great 1.5 time control ( except therapeutically anticoagulated nonrelated medical condition [ e.g. , atrial fibrillation ] ) Hepatic : Bilirubin great 3.0 mg/dL Renal : Creatinine great 2.5 mg/dL Other : Not pregnant nursing Negative pregnancy test No pacemaker , cerebral aneurysm clip , shrapnel injury , implantable electronic device No know uncontrollable serious reaction ( e.g. , anaphylaxis ) contrast agent use study Weight le 136 kg PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Concurrent systemic therapy extrahepatic disease allow begin prior radiofrequency ablation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>